SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Rakhee Krishna, Manal Ali, Ahmed A. Moustafa, Effects of combined MAO-B inhibitors and levodopa vs. monotherapy in Parkinson’s disease, Frontiers in Aging Neuroscience, 2014, 6,

    CrossRef

  2. 2
    Philip C. Buttery, Roger A. Barker, Treating Parkinson's disease in the 21st century: Can stem cell transplantation compete?, Journal of Comparative Neurology, 2014, 522, 12
  3. 3
    Ahmed A. Moustafa, Mohammad M. Herzallah, Mark A. Gluck, Dissociating the Cognitive Effects of Levodopa versus Dopamine Agonists in a Neurocomputational Model of Learning in Parkinson’s Disease, Neurodegenerative Diseases, 2013, 11, 2, 102

    CrossRef

  4. 4
    S. K. Sudakov, V. G. Bashkatova, Effect of Peripheral D2 Dopamine Receptor Antagonist Domperidone on Metabolism, Feeding Behavior, and Locomotor Activity of Rats, Bulletin of Experimental Biology and Medicine, 2013, 155, 6, 705

    CrossRef

  5. 5
    Pauline Belujon, Anthony A. Grace, l-dopa treatment duration versus Parkinson's disease progression: The dorsal-ventral divide, Movement Disorders, 2013, 28, 2
  6. 6
    Thomas Müller, Sören Peters, Ali Harati, Levodopa increases speed of alternating movements in Parkinson’s disease patients, Journal of Neural Transmission, 2013, 120, 2, 309

    CrossRef

  7. 7
    K. Ray Chaudhuri, Alexandra Rizos, Kapil D. Sethi, Motor and nonmotor complications in Parkinson’s disease: an argument for continuous drug delivery?, Journal of Neural Transmission, 2013, 120, 9, 1305

    CrossRef

  8. 8
    H. G. Laurie Rauch, Georg Schönbächler, Timothy D. Noakes, Neural Correlates of Motor Vigour and Motor Urgency During Exercise, Sports Medicine, 2013, 43, 4, 227

    CrossRef

  9. 9
    Aaron Kucinski, Scott Wersinger, Ewa K. Stachowiak, Thomas D. Corso, Matthew J. Parry, Jenny Zhang, Kristen Jordan, Sharon Letchworth, Merouane Bencherif, Michal K. Stachowiak, Neuronal nicotinic receptor agonists ameliorate spontaneous motor asymmetries and motor discoordination in a unilateral mouse model of Parkinson's disease, Pharmacology Biochemistry and Behavior, 2013, 111, 1

    CrossRef

  10. 10
    Paolo Calabresi, Anna Castrioto, Massimiliano Di Filippo, Barbara Picconi, New experimental and clinical links between the hippocampus and the dopaminergic system in Parkinson's disease, The Lancet Neurology, 2013, 12, 8, 811

    CrossRef

  11. 11
    S.E. Sander, C. Lemm, N. Lange, M. Hamann, A. Richter, Retigabine, a KV7 (KCNQ) potassium channel opener, attenuates l-DOPA-induced dyskinesias in 6-OHDA-lesioned rats, Neuropharmacology, 2012, 62, 2, 1052

    CrossRef

  12. 12
    M.M. Iravani, A.C. McCreary, P. Jenner, Striatal plasticity in Parkinson's disease and L-DOPA induced dyskinesia, Parkinsonism & Related Disorders, 2012, 18, S123

    CrossRef

  13. 13
    Aaron Kucinski, Scott Wersinger, Ewa K. Stachowiak, Milen Radell, Renae Hesse, Thomas Corso, Matthew Parry, Merouane Bencherif, Kristen Jordan, Sharon Letchworth, Michal K. Stachowiak, Unilateral 6-OHDA <i>th-fgfr1</i>(<i>tk-</i>) mouse model supports the role of FGFs in Parkinson’s disease and the effects of nicotine and L-DOPA on spontaneous motor impairments, Health, 2012, 04, 11, 1178

    CrossRef

  14. 14
    Ahmed A. Moustafa, Mark A. Gluck, Computational cognitive models of prefrontal-striatal-hippocampal interactions in Parkinson’s disease and schizophrenia, Neural Networks, 2011, 24, 6, 575

    CrossRef

  15. 15
    P. Jenner, A. C. McCreary, D. K. A. Scheller, Continuous drug delivery in early- and late-stage Parkinson’s disease as a strategy for avoiding dyskinesia induction and expression, Journal of Neural Transmission, 2011, 118, 12, 1691

    CrossRef

  16. 16
    Ángel Sesar, José Matías Arbelo, Javier López del Val, Treatment of Parkinson Disease, Time and Dosage, The Neurologist, 2011, 17, S43

    CrossRef

  17. 17
    Emanuele Cereda, Michela Barichella, Carlo Pedrolli, Gianni Pezzoli, Low-protein and protein-redistribution diets for Parkinson's disease patients with motor fluctuations: A systematic review, Movement Disorders, 2010, 25, 13
  18. 18
    P. Barone, Neurotransmission in Parkinson’s disease: beyond dopamine, European Journal of Neurology, 2010, 17, 3
  19. 19
    Kwamivi Dzahini, Christine Dentresangle, Marion Le Cavorsin, Anne Bertrand, Isabelle Detraz, Marc Savasta, Vincent Leviel, Pre-synaptic glutamate-induced activation of DA release in the striatum after partial nigral lesion, Journal of Neurochemistry, 2010, 113, 6
  20. 20
    F.E. Padovan-Neto, M.B. Echeverry, V. Tumas, E.A. Del-Bel, Nitric oxide synthase inhibition attenuates l-DOPA-induced dyskinesias in a rodent model of Parkinson's disease, Neuroscience, 2009, 159, 3, 927

    CrossRef

  21. 21
    Alain Dagher, Trevor W. Robbins, Personality, Addiction, Dopamine: Insights from Parkinson's Disease, Neuron, 2009, 61, 4, 502

    CrossRef